Cargando…
Protective antibodies against Eastern equine encephalitis virus bind to epitopes in domains A and B of the E2 glycoprotein
Eastern equine encephalitis virus (EEEV) is a mosquito-transmitted alphavirus with a high case mortality rate in humans. EEEV is a biodefense concern because of its potential for aerosol spread and the lack of existing countermeasures. In this study, we identified a panel of 18 neutralizing murine m...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294662/ https://www.ncbi.nlm.nih.gov/pubmed/30455470 http://dx.doi.org/10.1038/s41564-018-0286-4 |
_version_ | 1783380771267936256 |
---|---|
author | Kim, Arthur S. Austin, S. Kyle Gardner, Christina L. Zuiani, Adam Reed, Douglas S. Trobaugh, Derek W. Sun, Chengqun Basore, Katherine Williamson, Lauren E. Crowe, James E. Slifka, Mark K. Fremont, Daved H. Klimstra, William B. Diamond, Michael S. |
author_facet | Kim, Arthur S. Austin, S. Kyle Gardner, Christina L. Zuiani, Adam Reed, Douglas S. Trobaugh, Derek W. Sun, Chengqun Basore, Katherine Williamson, Lauren E. Crowe, James E. Slifka, Mark K. Fremont, Daved H. Klimstra, William B. Diamond, Michael S. |
author_sort | Kim, Arthur S. |
collection | PubMed |
description | Eastern equine encephalitis virus (EEEV) is a mosquito-transmitted alphavirus with a high case mortality rate in humans. EEEV is a biodefense concern because of its potential for aerosol spread and the lack of existing countermeasures. In this study, we identified a panel of 18 neutralizing murine monoclonal antibodies (mAbs) against the EEEV E2 protein, several of which had “elite” activity with 50% and 99% inhibitory concentrations (EC(50) and EC(99)) of less than 10 and 100 ng/ml, respectively. Alanine-scanning mutagenesis and neutralization escape mapping analysis revealed epitopes for these mAbs in domains A or B of the E2 glycoprotein. A majority of the neutralizing mAbs blocked at a post-attachment stage, with several inhibiting viral membrane fusion. Administration of one dose of anti-EEEV mAbs protected mice from lethal subcutaneous or aerosol challenge. These experiments define the mechanistic basis for neutralization by protective anti-EEEV mAbs and suggest a path forward for treatment and vaccine design. |
format | Online Article Text |
id | pubmed-6294662 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
record_format | MEDLINE/PubMed |
spelling | pubmed-62946622019-05-19 Protective antibodies against Eastern equine encephalitis virus bind to epitopes in domains A and B of the E2 glycoprotein Kim, Arthur S. Austin, S. Kyle Gardner, Christina L. Zuiani, Adam Reed, Douglas S. Trobaugh, Derek W. Sun, Chengqun Basore, Katherine Williamson, Lauren E. Crowe, James E. Slifka, Mark K. Fremont, Daved H. Klimstra, William B. Diamond, Michael S. Nat Microbiol Article Eastern equine encephalitis virus (EEEV) is a mosquito-transmitted alphavirus with a high case mortality rate in humans. EEEV is a biodefense concern because of its potential for aerosol spread and the lack of existing countermeasures. In this study, we identified a panel of 18 neutralizing murine monoclonal antibodies (mAbs) against the EEEV E2 protein, several of which had “elite” activity with 50% and 99% inhibitory concentrations (EC(50) and EC(99)) of less than 10 and 100 ng/ml, respectively. Alanine-scanning mutagenesis and neutralization escape mapping analysis revealed epitopes for these mAbs in domains A or B of the E2 glycoprotein. A majority of the neutralizing mAbs blocked at a post-attachment stage, with several inhibiting viral membrane fusion. Administration of one dose of anti-EEEV mAbs protected mice from lethal subcutaneous or aerosol challenge. These experiments define the mechanistic basis for neutralization by protective anti-EEEV mAbs and suggest a path forward for treatment and vaccine design. 2018-11-19 2019-01 /pmc/articles/PMC6294662/ /pubmed/30455470 http://dx.doi.org/10.1038/s41564-018-0286-4 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Kim, Arthur S. Austin, S. Kyle Gardner, Christina L. Zuiani, Adam Reed, Douglas S. Trobaugh, Derek W. Sun, Chengqun Basore, Katherine Williamson, Lauren E. Crowe, James E. Slifka, Mark K. Fremont, Daved H. Klimstra, William B. Diamond, Michael S. Protective antibodies against Eastern equine encephalitis virus bind to epitopes in domains A and B of the E2 glycoprotein |
title | Protective antibodies against Eastern equine encephalitis virus bind to epitopes in domains A and B of the E2 glycoprotein |
title_full | Protective antibodies against Eastern equine encephalitis virus bind to epitopes in domains A and B of the E2 glycoprotein |
title_fullStr | Protective antibodies against Eastern equine encephalitis virus bind to epitopes in domains A and B of the E2 glycoprotein |
title_full_unstemmed | Protective antibodies against Eastern equine encephalitis virus bind to epitopes in domains A and B of the E2 glycoprotein |
title_short | Protective antibodies against Eastern equine encephalitis virus bind to epitopes in domains A and B of the E2 glycoprotein |
title_sort | protective antibodies against eastern equine encephalitis virus bind to epitopes in domains a and b of the e2 glycoprotein |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294662/ https://www.ncbi.nlm.nih.gov/pubmed/30455470 http://dx.doi.org/10.1038/s41564-018-0286-4 |
work_keys_str_mv | AT kimarthurs protectiveantibodiesagainsteasternequineencephalitisvirusbindtoepitopesindomainsaandbofthee2glycoprotein AT austinskyle protectiveantibodiesagainsteasternequineencephalitisvirusbindtoepitopesindomainsaandbofthee2glycoprotein AT gardnerchristinal protectiveantibodiesagainsteasternequineencephalitisvirusbindtoepitopesindomainsaandbofthee2glycoprotein AT zuianiadam protectiveantibodiesagainsteasternequineencephalitisvirusbindtoepitopesindomainsaandbofthee2glycoprotein AT reeddouglass protectiveantibodiesagainsteasternequineencephalitisvirusbindtoepitopesindomainsaandbofthee2glycoprotein AT trobaughderekw protectiveantibodiesagainsteasternequineencephalitisvirusbindtoepitopesindomainsaandbofthee2glycoprotein AT sunchengqun protectiveantibodiesagainsteasternequineencephalitisvirusbindtoepitopesindomainsaandbofthee2glycoprotein AT basorekatherine protectiveantibodiesagainsteasternequineencephalitisvirusbindtoepitopesindomainsaandbofthee2glycoprotein AT williamsonlaurene protectiveantibodiesagainsteasternequineencephalitisvirusbindtoepitopesindomainsaandbofthee2glycoprotein AT crowejamese protectiveantibodiesagainsteasternequineencephalitisvirusbindtoepitopesindomainsaandbofthee2glycoprotein AT slifkamarkk protectiveantibodiesagainsteasternequineencephalitisvirusbindtoepitopesindomainsaandbofthee2glycoprotein AT fremontdavedh protectiveantibodiesagainsteasternequineencephalitisvirusbindtoepitopesindomainsaandbofthee2glycoprotein AT klimstrawilliamb protectiveantibodiesagainsteasternequineencephalitisvirusbindtoepitopesindomainsaandbofthee2glycoprotein AT diamondmichaels protectiveantibodiesagainsteasternequineencephalitisvirusbindtoepitopesindomainsaandbofthee2glycoprotein |